Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 383

1.

LAT1-specific inhibitor is effective against T cell-mediated allergic skin inflammation.

Hayashi K, Kaminuma O, Nishimura T, Saeki M, Matsuoka K, Hiroi T, Jutabha P, Iwata Y, Sugiura K, Owada T, Kurasawa K, Okayasu I, Ouchi M, Fujita T, Kanai Y, Endou H, Anzai N.

Allergy. 2019 Aug 12. doi: 10.1111/all.14019. [Epub ahead of print] No abstract available.

PMID:
31403710
2.

Cryo-EM structure of the human L-type amino acid transporter 1 in complex with glycoprotein CD98hc.

Lee Y, Wiriyasermkul P, Jin C, Quan L, Ohgaki R, Okuda S, Kusakizako T, Nishizawa T, Oda K, Ishitani R, Yokoyama T, Nakane T, Shirouzu M, Endou H, Nagamori S, Kanai Y, Nureki O.

Nat Struct Mol Biol. 2019 Jun;26(6):510-517. doi: 10.1038/s41594-019-0237-7. Epub 2019 Jun 3.

PMID:
31160781
3.

Inhibition of the amino-acid transporter LAT1 demonstrates anti-neoplastic activity in medulloblastoma.

Cormerais Y, Pagnuzzi-Boncompagni M, Schrötter S, Giuliano S, Tambutté E, Endou H, Wempe MF, Pagès G, Pouysségur J, Picco V.

J Cell Mol Med. 2019 Apr;23(4):2711-2718. doi: 10.1111/jcmm.14176. Epub 2019 Feb 19.

4.

The glutamine transporter ASCT2 (SLC1A5) promotes tumor growth independently of the amino acid transporter LAT1 (SLC7A5).

Cormerais Y, Massard PA, Vucetic M, Giuliano S, Tambutté E, Durivault J, Vial V, Endou H, Wempe MF, Parks SK, Pouyssegur J.

J Biol Chem. 2018 Feb 23;293(8):2877-2887. doi: 10.1074/jbc.RA117.001342. Epub 2018 Jan 11.

5.

JPH203, a selective L-type amino acid transporter 1 inhibitor, induces mitochondria-dependent apoptosis in Saos2 human osteosarcoma cells.

Choi DW, Kim DK, Kanai Y, Wempe MF, Endou H, Kim JK.

Korean J Physiol Pharmacol. 2017 Nov;21(6):599-607. doi: 10.4196/kjpp.2017.21.6.599. Epub 2017 Oct 30.

6.

Co-targeting intracellular pH and essential amino acid uptake cooperates to induce cell death of T-ALL/LL cells.

Imbert V, Nebout M, Mary D, Endou H, Wempe MF, Supuran CT, Winum JY, Peyron JF.

Leuk Lymphoma. 2018 Feb;59(2):460-468. doi: 10.1080/10428194.2017.1339875. Epub 2017 Jun 22.

PMID:
28641473
7.

Inhibition of l-type amino acid transporter 1 activity as a new therapeutic target for cholangiocarcinoma treatment.

Yothaisong S, Dokduang H, Anzai N, Hayashi K, Namwat N, Yongvanit P, Sangkhamanon S, Jutabha P, Endou H, Loilome W.

Tumour Biol. 2017 Mar;39(3):1010428317694545. doi: 10.1177/1010428317694545.

PMID:
28347255
8.

Ultrastructural immunohistochemical study of L-type amino acid transporter 1-4F2 heavy chain in tumor microvasculatures of N-butyl-N-(4-hydroxybutyl) nitrosamine (BBN) induced rat bladder carcinoma.

Kume E, Mutou T, Kansaku N, Takahashi H, Wempe MF, Ikegami M, Kanai Y, Endou H, Wakui S.

Microscopy (Oxf). 2017 Jun 1;66(3):198-203. doi: 10.1093/jmicro/dfx008.

PMID:
28339760
9.

LAT1 acts as a crucial transporter of amino acids in human thymic carcinoma cells.

Hayashi K, Jutabha P, Maeda S, Supak Y, Ouchi M, Endou H, Fujita T, Chida M, Anzai N.

J Pharmacol Sci. 2016 Nov;132(3):201-204. doi: 10.1016/j.jphs.2016.07.006. Epub 2016 Jul 27.

10.

Genetic Disruption of the Multifunctional CD98/LAT1 Complex Demonstrates the Key Role of Essential Amino Acid Transport in the Control of mTORC1 and Tumor Growth.

Cormerais Y, Giuliano S, LeFloch R, Front B, Durivault J, Tambutté E, Massard PA, de la Ballina LR, Endou H, Wempe MF, Palacin M, Parks SK, Pouyssegur J.

Cancer Res. 2016 Aug 1;76(15):4481-92. doi: 10.1158/0008-5472.CAN-15-3376. Epub 2016 Jun 14. Erratum in: Cancer Res. 2017 Jul 1;77(13):3721.

11.

Metformin enhances anti-tumor effect of L-type amino acid transporter 1 (LAT1) inhibitor.

Ueno S, Kimura T, Yamaga T, Kawada A, Ochiai T, Endou H, Sakurai H.

J Pharmacol Sci. 2016 Jun;131(2):110-7. doi: 10.1016/j.jphs.2016.04.021. Epub 2016 May 10.

12.

HOXB9 acts as a negative regulator of activated human T cells in response to amino acid deficiency.

Hayashi K, Ouchi M, Endou H, Anzai N.

Immunol Cell Biol. 2016 Jul;94(6):612-7. doi: 10.1038/icb.2016.13. Epub 2016 Mar 1.

PMID:
26926958
13.

L-Type amino acid transporter 1 (LAT1) expression in lymph node metastasis of gastric carcinoma: Its correlation with size of metastatic lesion and Ki-67 labeling.

Ichinoe M, Yanagisawa N, Mikami T, Hana K, Nakada N, Endou H, Okayasu I, Murakumo Y.

Pathol Res Pract. 2015 Jul;211(7):533-8. doi: 10.1016/j.prp.2015.03.007. Epub 2015 Apr 7.

PMID:
25908107
14.

L-amino acid transporter 1 may be a prognostic marker for local progression of prostatic cancer under expectant management.

Yanagisawa N, Satoh T, Hana K, Ichinoe M, Nakada N, Endou H, Okayasu I, Murakumo Y.

Cancer Biomark. 2015;15(4):365-74. doi: 10.3233/CBM-150486.

PMID:
25835180
15.

L-type amino-acid transporter 1 (LAT1): a therapeutic target supporting growth and survival of T-cell lymphoblastic lymphoma/T-cell acute lymphoblastic leukemia.

Rosilio C, Nebout M, Imbert V, Griessinger E, Neffati Z, Benadiba J, Hagenbeek T, Spits H, Reverso J, Ambrosetti D, Michiels JF, Bailly-Maitre B, Endou H, Wempe MF, Peyron JF.

Leukemia. 2015 Jun;29(6):1253-66. doi: 10.1038/leu.2014.338. Epub 2014 Dec 8.

PMID:
25482130
16.

Hyperoxia inhibits nitric oxide treatment effects in alveolar epithelial cells via effects on L-type amino acid transporter-1.

Brahmajothi MV, Tinch BT, Wempe MF, Endou H, Auten RL.

Antioxid Redox Signal. 2014 Nov 1;21(13):1823-36. doi: 10.1089/ars.2013.5664. Epub 2014 Sep 22.

17.

High expression of L-type amino acid transporter 1 as a prognostic marker in bile duct adenocarcinomas.

Yanagisawa N, Hana K, Nakada N, Ichinoe M, Koizumi W, Endou H, Okayasu I, Murakumo Y.

Cancer Med. 2014 Oct;3(5):1246-55. doi: 10.1002/cam4.272. Epub 2014 Jun 2.

18.

L-type amino acid transporter 1 expression increases in well-differentiated but decreases in poorly differentiated endometrial endometrioid adenocarcinoma and shows an inverse correlation with p53 expression.

Watanabe J, Yokoyama Y, Futagami M, Mizunuma H, Yoshioka H, Washiya K, Hana K, Endou H, Okayasu I.

Int J Gynecol Cancer. 2014 May;24(4):659-63. doi: 10.1097/IGC.0000000000000123.

PMID:
24694899
19.

LAT1 is a central transporter of essential amino acids in human umbilical vein endothelial cells.

Hayashi K, Jutabha P, Kamai T, Endou H, Anzai N.

J Pharmacol Sci. 2014;124(4):511-3. Epub 2014 Mar 27.

20.

Nuclear Morphometric Analysis of Leydig Cells of Male Pubertal Rats Exposed In Utero to Di(n-butyl) Phthalate.

Wakui S, Motohashi M, Satoh T, Shirai M, Mutou T, Takahashi H, Wempe MF, Endou H, Inomata T, Asari M.

J Toxicol Pathol. 2013 Dec;26(4):439-46. doi: 10.1293/tox.2013-0031. Epub 2013 Dec 26.

21.

JPH203, an L-type amino acid transporter 1-selective compound, induces apoptosis of YD-38 human oral cancer cells.

Yun DW, Lee SA, Park MG, Kim JS, Yu SK, Park MR, Kim SG, Oh JS, Kim CS, Kim HJ, Kim JS, Chun HS, Kanai Y, Endou H, Wempe MF, Kim DK.

J Pharmacol Sci. 2014;124(2):208-17. Epub 2014 Feb 4.

22.

Effects of in utero exposure to di(n-butyl) phthalate for estrogen receptors α, β, and androgen receptor of Leydig cell on rats.

Wakui S, Shirai M, Motohashi M, Mutou T, Oyama N, Wempe MF, Takahashi H, Inomata T, Ikegami M, Endou H, Asari M.

Toxicol Pathol. 2014 Jul;42(5):877-87. doi: 10.1177/0192623313502879. Epub 2013 Sep 25.

PMID:
24067674
23.

LAT1 is a critical transporter of essential amino acids for immune reactions in activated human T cells.

Hayashi K, Jutabha P, Endou H, Sagara H, Anzai N.

J Immunol. 2013 Oct 15;191(8):4080-5. doi: 10.4049/jimmunol.1300923. Epub 2013 Sep 13.

24.

Unique and selective expression of L-amino acid transporter 1 in human tissue as well as being an aspect of oncofetal protein.

Nakada N, Mikami T, Hana K, Ichinoe M, Yanagisawa N, Yoshida T, Endou H, Okayasu I.

Histol Histopathol. 2014 Feb;29(2):217-27. doi: 10.14670/HH-29.217. Epub 2013 Jul 5.

PMID:
23824658
25.

Investigation of the role of transporters on the hepatic elimination of an LAT1 selective inhibitor JPH203.

Toyoshima J, Kusuhara H, Wempe MF, Endou H, Sugiyama Y.

J Pharm Sci. 2013 Sep;102(9):3228-38. doi: 10.1002/jps.23601. Epub 2013 May 27.

PMID:
23712732
26.

Male Sprague-Dawley rats exposed to in utero di(n-butyl) phthalate: dose dependent and age-related morphological changes in Leydig cell smooth endoplasmic reticulum.

Shirai M, Wakui S, Wempe MF, Mutou T, Oyama N, Motohashi M, Takahashi H, Kansaku N, Asari M, Hano H, Endou H.

Toxicol Pathol. 2013;41(7):984-91. doi: 10.1177/0192623312474725. Epub 2013 Feb 15.

PMID:
23416961
27.

Potent human uric acid transporter 1 inhibitors: in vitro and in vivo metabolism and pharmacokinetic studies.

Wempe MF, Lightner JW, Miller B, Iwen TJ, Rice PJ, Wakui S, Anzai N, Jutabha P, Endou H.

Drug Des Devel Ther. 2012;6:323-39. doi: 10.2147/DDDT.S35805. Epub 2012 Nov 8.

28.

Atypical Leydig cell hyperplasia in adult rats with low T and high LH induced by prenatal Di(n-butyl) phthalate exposure.

Wakui S, Takahashi H, Mutou T, Shirai M, Jutabha P, Anzai N, Wempe MF, Kansaku N, Hano H, Inomata T, Endou H.

Toxicol Pathol. 2013;41(3):480-6. doi: 10.1177/0192623312457272. Epub 2012 Sep 11.

PMID:
22968287
29.

[Cardiac failure caused by intrapericardial chronic expanding hematoma 18 years after CABG].

Ono H, Abe H, Sakurai Y, Endou H, Chiba K, Oono M, Kitanaka Y, Makuuchi H.

Kyobu Geka. 2012 Sep;65(10):885-9. Japanese.

PMID:
22940660
30.

High expression of L-type amino acid transporter 1 (LAT1) predicts poor prognosis in pancreatic ductal adenocarcinomas.

Yanagisawa N, Ichinoe M, Mikami T, Nakada N, Hana K, Koizumi W, Endou H, Okayasu I.

J Clin Pathol. 2012 Nov;65(11):1019-23. doi: 10.1136/jclinpath-2012-200826. Epub 2012 Jul 19.

PMID:
22813728
31.

Transport of 3-fluoro-L-α-methyl-tyrosine by tumor-upregulated L-type amino acid transporter 1: a cause of the tumor uptake in PET.

Wiriyasermkul P, Nagamori S, Tominaga H, Oriuchi N, Kaira K, Nakao H, Kitashoji T, Ohgaki R, Tanaka H, Endou H, Endo K, Sakurai H, Kanai Y.

J Nucl Med. 2012 Aug;53(8):1253-61. doi: 10.2967/jnumed.112.103069. Epub 2012 Jun 28.

32.

c-Myc is crucial for the expression of LAT1 in MIA Paca-2 human pancreatic cancer cells.

Hayashi K, Jutabha P, Endou H, Anzai N.

Oncol Rep. 2012 Sep;28(3):862-6. doi: 10.3892/or.2012.1878. Epub 2012 Jun 20.

PMID:
22736142
33.

Sex-associated difference in estrogen receptor β expression in N-methyl-N'-nitro-N-nitrosoguanidine-induced gastric cancers in rats.

Wakui S, Motohashi M, Muto T, Takahashi H, Hano H, Jutabha P, Anzai N, Wempe MF, Endou H.

Comp Med. 2011 Oct;61(5):412-8.

34.

Human uric acid transporter 1 (hURAT1): an inhibitor structure-activity relationship (SAR) study.

Wempe MF, Quade B, Jutabha P, Iwen T, Frick M, Rice PJ, Wakui S, Endou H.

Nucleosides Nucleotides Nucleic Acids. 2011 Dec;30(12):1312-23. doi: 10.1080/15257770.2011.594031.

PMID:
22132992
35.

Apical voltage-driven urate efflux transporter NPT4 in renal proximal tubule.

Jutabha P, Anzai N, Wempe MF, Wakui S, Endou H, Sakurai H.

Nucleosides Nucleotides Nucleic Acids. 2011 Dec;30(12):1302-11. doi: 10.1080/15257770.2011.616564. Review.

PMID:
22132991
36.

Urate transporters: an evolving field.

Anzai N, Endou H.

Semin Nephrol. 2011 Sep;31(5):400-9. doi: 10.1016/j.semnephrol.2011.08.003. Review.

PMID:
22000646
37.

Metabolism and pharmacokinetic studies of JPH203, an L-amino acid transporter 1 (LAT1) selective compound.

Wempe MF, Rice PJ, Lightner JW, Jutabha P, Hayashi M, Anzai N, Wakui S, Kusuhara H, Sugiyama Y, Endou H.

Drug Metab Pharmacokinet. 2012;27(1):155-61. Epub 2011 Sep 13.

38.

A novel human organic anion transporter NPT4 mediates the transport of ochratoxin A.

Jutabha P, Anzai N, Hayashi K, Domae M, Uchida K, Endou H, Sakurai H.

J Pharmacol Sci. 2011;116(4):392-6. Epub 2011 Jul 21.

39.

High expression of L-type amino-acid transporter 1 (LAT1) in gastric carcinomas: comparison with non-cancerous lesions.

Ichinoe M, Mikami T, Yoshida T, Igawa I, Tsuruta T, Nakada N, Anzai N, Suzuki Y, Endou H, Okayasu I.

Pathol Int. 2011 May;61(5):281-9. doi: 10.1111/j.1440-1827.2011.02650.x. Epub 2011 Mar 17.

PMID:
21501294
40.

Developing potent human uric acid transporter 1 (hURAT1) inhibitors.

Wempe MF, Jutabha P, Quade B, Iwen TJ, Frick MM, Ross IR, Rice PJ, Anzai N, Endou H.

J Med Chem. 2011 Apr 28;54(8):2701-13. doi: 10.1021/jm1015022. Epub 2011 Mar 30.

41.

Role of amino acid transporter LAT2 in the activation of mTORC1 pathway and the pathogenesis of crescentic glomerulonephritis.

Kurayama R, Ito N, Nishibori Y, Fukuhara D, Akimoto Y, Higashihara E, Ishigaki Y, Sai Y, Miyamoto K, Endou H, Kanai Y, Yan K.

Lab Invest. 2011 Jul;91(7):992-1006. doi: 10.1038/labinvest.2011.43. Epub 2011 Mar 14.

42.

Human urate transporter 1 (hURAT1) mediates the transport of orotate.

Miura D, Anzai N, Jutabha P, Chanluang S, He X, Fukutomi T, Endou H.

J Physiol Sci. 2011 May;61(3):253-7. doi: 10.1007/s12576-011-0136-0. Epub 2011 Feb 25.

PMID:
21350910
43.

Functional analysis of human sodium-phosphate transporter 4 (NPT4/SLC17A3) polymorphisms.

Jutabha P, Anzai N, Kimura T, Taniguchi A, Urano W, Yamanaka H, Endou H, Sakurai H.

J Pharmacol Sci. 2011;115(2):249-53. Epub 2011 Jan 26.

44.

Interactions of urate transporter URAT1 in human kidney with uricosuric drugs.

Shin HJ, Takeda M, Enomoto A, Fujimura M, Miyazaki H, Anzai N, Endou H.

Nephrology (Carlton). 2011 Feb;16(2):156-62. doi: 10.1111/j.1440-1797.2010.01368.x.

PMID:
21272127
45.

Human sodium phosphate transporter 4 (hNPT4/SLC17A3) as a common renal secretory pathway for drugs and urate.

Jutabha P, Anzai N, Kitamura K, Taniguchi A, Kaneko S, Yan K, Yamada H, Shimada H, Kimura T, Katada T, Fukutomi T, Tomita K, Urano W, Yamanaka H, Seki G, Fujita T, Moriyama Y, Yamada A, Uchida S, Wempe MF, Endou H, Sakurai H.

J Biol Chem. 2010 Nov 5;285(45):35123-32. doi: 10.1074/jbc.M110.121301. Epub 2010 Sep 1.

46.

Inhibition of L-type amino acid transporter modulates the expression of cell cycle regulatory factors in KB oral cancer cells.

Kim CS, Moon IS, Park JH, Shin WC, Chun HS, Lee SY, Kook JK, Kim HJ, Park JC, Endou H, Kanai Y, Lee BK, Kim DK.

Biol Pharm Bull. 2010;33(7):1117-21.

47.

Functional analysis of human organic cation transporter OCT3 (SLC22A3) polymorphisms.

Sakata T, Anzai N, Kimura T, Miura D, Fukutomi T, Takeda M, Sakurai H, Endou H.

J Pharmacol Sci. 2010;113(3):263-6. Epub 2010 Jun 16.

48.

[Human renal urate transpoter URAT1 mediates the transport of salicylate].

Ohtsu N, Anzai N, Fukutomi T, Kimura T, Sakurai H, Endou H.

Nihon Jinzo Gakkai Shi. 2010;52(4):499-504. Japanese.

PMID:
20560471
49.

Molecular mechanism of ochratoxin a transport in the kidney.

Anzai N, Jutabha P, Endou H.

Toxins (Basel). 2010 Jun;2(6):1381-98. doi: 10.3390/toxins2061381. Epub 2010 Jun 9.

50.

Interactions of human organic anion transporters with aristolochic acids.

Babu E, Takeda M, Nishida R, Noshiro-Kofuji R, Yoshida M, Ueda S, Fukutomi T, Anzai N, Endou H.

J Pharmacol Sci. 2010;113(2):192-6. Epub 2010 May 28.

Supplemental Content

Support Center